At AAOS Knee Implant Makers Pitch Better Fit, Precision

Once beyond reproach, knee replacement surgeries are getting a long, hard look by surgeons, researchers, and companies trying to determine whether success rates that exceed 90% can be improved upon by using customized implants or surgical robots.

Zimmer Biomet Holdings Inc.parked a casino in the center of the exhibit hall at last month’s American Academy of Orthopaedic Surgeons (AAOS). At least it looked like a casino; or perhaps a cruise ship. Whatever your chosen imagery, Zimmer certainly went BIG to trumpet the arrival of its Persona knee system. Wall Street analysts and surgeons may disagree about whether the implants represent an evolutionary or revolutionary step for the company’s knee line. But the pomp and circumstance surrounding the launch represented the growing appetite for new lines of knee implants and surgeries as well as the increasing importance marketing efforts will have in the success of these new products. (See Also see "At AAOS, Large Joint Makers Are Making It Personal" - In Vivo, 24 February, 2012..)

Once beyond reproach, knee replacement surgeries – both total and partial – are getting a long, hard look by surgeons, researchers, and companies trying to determine whether success rates that...

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.